



SAN DIEGO'S NATIONAL CANCER INSTITUTE - DESIGNATED CANCER CENTERS



2017 C3 Collaborative Translational Cancer Research Awards

Request for Applications (RFA)

Deadline: April 28, 2017 @ 5:00 PM (PST)

PURPOSE: Proceeds from the November 2016 Padres Pedal the Cause are available to faculty members of the Salk, Moores, and Sanford Burnham Prebys (SBP) Cancer Centers (San Diego NCI Cancer Centers Council or C3), Rady Children's Hospital, and C3 members from UC San Diego-affiliated institutions (JCVI, LJI, SIO, SDSU) to stimulate scientific collaboration, team science, and innovative translational research related to the prevention, diagnosis, or treatment of cancer. Where relevant, proposed research projects should describe use of the C3 Shared Resources found on the C3 website (<http://sdcancercouncil.org>). Priority will be given to proposals that have a high likelihood of leading to extramural research funding, provide new approaches to important clinical or population/community challenges, or offer a clear route to a clinical trial.

- Proposals led by **Moore's Cancer Center (MCC) population science** faculty in collaboration with Salk and/or SBP faculty are highly encouraged and will be reviewed by investigators with appropriate expertise and weighed more heavily if it is particularly meritorious.

2017 C3 PILOT GRANTS FUNDS AVAILABLE:

At least **five** (5) awards up to \$75K for one (1) year are expected to be funded in 2017.

PROPOSAL REQUIREMENTS: Applications must include PIs (C3 cancer center members) from at least two (2) of the cancer centers. Given the translational/clinical nature of the proposed research, **one (1) PI must be a cancer center member from the MCC or Rady Children's Hospital**. Links to C3 members and their areas of interest can be found on the C3 website.

- Scientific Abstract (up to 250 words)
- Lay Abstract (up to 250 words); describe in lay language the potential impact of the project on cancer treatment, prevention and diagnosis in the short and long term.
- Specific Aims (up to 1 page); include goals, hypotheses, role of each PI and senior/key personnel, and expected outcomes.
- Research Strategy (up to 3 pages, **excluding references**), including significance, background/rationale, preliminary data and approaches (highlight non-routine approaches, summarize routine approaches, address statistical approaches and include statement(s) regarding study feasibility, e.g., tissue availability).
- Biosketch of each PI and senior/key personnel (NIH Standard 5-page Biosketch), including relevant recent publications and other **current** and **pending** support.
- Budget and Budget Justification (up to 2 pages); budget justification and summary for all major budget categories (e.g., salary, etc.) must be provided for each site. The application must also include a composite budget summary for all budget categories.
- For proposals involving a clinical trial, pertinent information must be included on: (a) intervention(s) to be used, reasons for the selection of intervention(s), and mode(s) of delivery; (b) study design, treatment group(s), trial size, and inclusion/exclusion criteria; (c) control group(s) if applicable; (d) outcome measures; and (e) data analysis plan if applicable. Awards can be leveraged with other funding sources for the clinical trial provided that feasibility (e.g., drug availability, accrual and timeline) is clearly outlined in the application.
- For proposals utilizing Biorepository specimens, a Biospecimen Request Form must be completed. The Biorepository and Tissue Technology Shared Resource website provides additional detail about resources that are available. Please contact the Biorepository Manager (Sharmeela Kaushal, PhD) at cabr@ad.ucsd.edu. Investigator must establish study feasibility (e.g., availability of suitable samples) to be included with the application.
- Any project proposing to study patients at UC San Diego Moores Cancer Center or Rady

Children's Hospital must have signed approval of the respective Disease Team Leaders declaring that the study is feasible based upon the proposed patient population, needed accrual, and competing funded studies. Where appropriate, physicians overseeing the care for these patients should be considered for co-investigator status.

C3 PILOT GRANT RULES:

1. A Co-PI may **submit only one (1) Pilot Grant application.**
2. 2016 C3 Pilot Grant **PI or** Co-PI awardees **are not eligible** to apply for the 2017 Pilot Grant awards.
3. Budget support for **each** C3 institution or Rady Children's must not be less than 30%.

PILOT GRANT EVALUATION CRITERIA:

- Scientific merit of the proposed research project and translational nature of the research, e.g., plan for translating the work from the laboratory to the clinic or community;
- Significance of the proposed research, i.e., whether it addresses a critical need for rapid progress beyond current approaches;
- Novelty of the hypothesis or methodology;
- Degree to which the studies will have a positive therapeutic impact on the detection, treatment or prevention of cancer;
- A clear commitment by grant awardees that all data resulting from their work will be available to the scientific community at large at the earliest opportunity;
- Likelihood that the research project will achieve its stated goals given the budget requested, institutional environments, and other resources available;
- Whether the studies are designed to capitalize upon the unique populations and environments, specialized expertise, new concepts and perspectives, innovative methodologies, and/or emerging technologies that are available due to the multi-institutional collaboration;
- Whether adequate institutional and/or financial support exists to sustain the research project;

APPLICATION GUIDELINES: The deadline is 5:00 PM PST, **FRIDAY, APRIL 28, 2017**. The earliest starting date is **JUNE 1, 2017**. All applications (pdf) must be submitted electronically via the MCC web-based pilot project review system called **WebGAAS**: <http://moores.ucsd.edu/Admin/grants-in-aid.asp>. Once an application has been submitted electronically via **WebGAAS**, it cannot be changed.

BUDGETARY GUIDELINES: The budget may include partial salary support for trainee investigators, laboratory technicians, and other related study expenses. **Travel, professional meeting fees, salary support for faculty and administrative personnel, and equipment are excluded.**

FORMAT SPECIFICATIONS: All applications must adhere to the following guidelines:

- Use Arial font 11 points or larger
- Use at least one-half inch margins (top, bottom, left and right) for all pages
- The application must be single-spaced and saved as a PDF
- Consecutively number pages in the Research Proposal
- As applicable, figures or other materials must be inserted directly into the body of the application
- No appendices

REVIEW CRITERIA: The C3 Steering Committee will conduct an NIH-style internal peer review of applications. The goal of the C3 RFA is to advance our understanding of cancer toward its prevention, diagnosis, and treatment and to foster the development of new team science approaches across the C3 member institutions.

USE OF FUNDS: The funds are to be used in general agreement with the research budget plan submitted with the application, but the Center will allow the investigator to re-budget reasonable amounts in accordance with his or her needs. A no-cost extension beyond the 1-year grant period is not automatic and must be requested a minimum of 60 days before the project end date.

HUMAN AND ANIMAL SUBJECTS, SAFETY, AND ENVIRONMENTAL HEALTH ISSUES: Pending IRB or IACUC approval or copies of IRB or IACUC approval must be submitted prior to activation of the grant award.

GRANTEE PROGRESS REPORTS: Reviews of work and progress will be made periodically but no less than annually. A progress report form will be sent to each PI towards the end of the funding year. This form must be completed, submitted, and approved prior to considering time extension (if requested).

PUBLICATIONS: All publications (as well as posters and abstracts at scientific meetings) that result from the support provided by this award must acknowledge that support in writing as follows: "San Diego NCI Cancer Centers Council (C3) #PTC2017"

EARLY TERMINATION OR TRANSFER OF RESEARCH FUNDS: If the grantee decides to discontinue the research project or leave UC San Diego, the Cancer Center must be notified immediately and the project will be terminated.

INQUIRIES:

- Leona Flores, PhD, C3 Grant Administrator
Email: leonaflores@ucsd.edu; Phone: 858 / 822-0182